-
Je něco špatně v tomto záznamu ?
Serum Biomarkers in Diagnosis and Clinical Management of Inflammatory Bowel Disease: Anything New on the Horizon
J. Ondriš, R. Husťak, J. Ďurina, E. Malicherová Jurková, V. Bošák
Jazyk angličtina Země Česko
Typ dokumentu časopisecké články, přehledy
NLK
Free Medical Journals
od 2000
Freely Accessible Science Journals
od 2000
ProQuest Central
od 2005-01-01
Health & Medicine (ProQuest)
od 2005-01-01
ROAD: Directory of Open Access Scholarly Resources
od 2000
PubMed
39889217
DOI
10.14712/fb2024070050248
Knihovny.cz E-zdroje
- MeSH
- biologické markery * krev MeSH
- feces chemie MeSH
- idiopatické střevní záněty * krev diagnóza MeSH
- leukocytární L1-antigenní komplex krev MeSH
- lidé MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- přehledy MeSH
Persistent inflammation in inflammatory bowel disease (IBD) leads to progressive damage to the gastrointestinal tract, resulting in potentially severe sequelae. Diagnosis primarily relies on invasive endoscopy and monitoring of faecal calprotectin (FC), which has limitations, particularly regarding patient compliance. There is a pressing need for a new biomarker that is non-invasive, easily determinable, and possesses good diagnostic accuracy for both dia-gnosing and monitoring IBD. Our narrative review covers the latest developments in novel serum biomarkers, focusing on those with promising diagnostic accuracy and laboratory methods, and evaluates them in the context of established biomarkers such as FC and CRP. Serum calprotectin (SC) and leucine-rich alpha-2 glycoprotein (LRG) show the most extensive evidence and relatively good diagnostic accuracy but currently cannot replace FC due to insufficient evidence. Major limitations of the analysed studies include their monocentric nature, small sample sizes, lack of longitudinal monitoring and in some cases, missing assessments of endoscopic activity. ELISA holds a leading position among the laboratory methods; however, emerging evidence supports the potential use of point-of-care testing (POCT). Establishing these biomarkers for regular clinical application will require further validation through multicentric studies involving a larger number of patients with a longitudinal design, concurrent assessment of endoscopic activity and pro-active monitoring of the biomarker. However, based on the evidence accumulated so far, SC might potentially serve as a complementary biomarker and/or in assessing the activity of extraintestinal manifestations in IBD patients, while LRG appears to be effective in evaluating endoscopic activity, especially in small bowel CD.
AstraZeneca AB o z Bratislava Slovakia
Gastroenterology and Hepatology Centre University Hospital with Polyclinic in Nové Zámky Slovakia
Gastroenterology Department Clinic of Internal Medicine University Hospital in Trnava Slovakia
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc25005463
- 003
- CZ-PrNML
- 005
- 20250521143030.0
- 007
- ta
- 008
- 250213s2024 xr d f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.14712/fb2024070050248 $2 doi
- 035 __
- $a (PubMed)39889217
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xr
- 100 1_
- $a Ondriš, Juraj $u AstraZeneca AB o.z., Bratislava, Slovakia. ondris.j@gmail.com $u Department of Laboratory Medicine, Faculty of Health Care and Social Work, Trnava University, Trnava, Slovakia. ondris.j@gmail.com $7 _AN122526
- 245 10
- $a Serum Biomarkers in Diagnosis and Clinical Management of Inflammatory Bowel Disease: Anything New on the Horizon / $c J. Ondriš, R. Husťak, J. Ďurina, E. Malicherová Jurková, V. Bošák
- 520 9_
- $a Persistent inflammation in inflammatory bowel disease (IBD) leads to progressive damage to the gastrointestinal tract, resulting in potentially severe sequelae. Diagnosis primarily relies on invasive endoscopy and monitoring of faecal calprotectin (FC), which has limitations, particularly regarding patient compliance. There is a pressing need for a new biomarker that is non-invasive, easily determinable, and possesses good diagnostic accuracy for both dia-gnosing and monitoring IBD. Our narrative review covers the latest developments in novel serum biomarkers, focusing on those with promising diagnostic accuracy and laboratory methods, and evaluates them in the context of established biomarkers such as FC and CRP. Serum calprotectin (SC) and leucine-rich alpha-2 glycoprotein (LRG) show the most extensive evidence and relatively good diagnostic accuracy but currently cannot replace FC due to insufficient evidence. Major limitations of the analysed studies include their monocentric nature, small sample sizes, lack of longitudinal monitoring and in some cases, missing assessments of endoscopic activity. ELISA holds a leading position among the laboratory methods; however, emerging evidence supports the potential use of point-of-care testing (POCT). Establishing these biomarkers for regular clinical application will require further validation through multicentric studies involving a larger number of patients with a longitudinal design, concurrent assessment of endoscopic activity and pro-active monitoring of the biomarker. However, based on the evidence accumulated so far, SC might potentially serve as a complementary biomarker and/or in assessing the activity of extraintestinal manifestations in IBD patients, while LRG appears to be effective in evaluating endoscopic activity, especially in small bowel CD.
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a biologické markery $x krev $7 D015415
- 650 12
- $a idiopatické střevní záněty $x krev $x diagnóza $7 D015212
- 650 _2
- $a leukocytární L1-antigenní komplex $x krev $7 D039841
- 650 _2
- $a feces $x chemie $7 D005243
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Husťak, Rastislav $u Department of Laboratory Medicine, Faculty of Health Care and Social Work, Trnava University, Trnava, Slovakia $u Gastroenterology Department, Clinic of Internal Medicine, University Hospital in Trnava, Slovakia $7 xx0229151
- 700 1_
- $a Ďurina, Juraj $u Gastroenterology and Hepatology Centre, University Hospital with Polyclinic in Nové Zámky, Slovakia $7 xx0077155
- 700 1_
- $a Jurková Malicherová, Eva $u Centre for Periodic Fever Syndromes, Department of Paediatrics, Jessenius Faculty of Medicine of Comenius University in Bratislava and University Hospital in Martin, Slovakia $7 xx0238239
- 700 1_
- $a Bošák, Vladimír $u Department of Laboratory Medicine, Faculty of Health Care and Social Work, Trnava University, Trnava, Slovakia $7 xx0128493
- 773 0_
- $w MED00011004 $t Folia biologica $x 0015-5500 $g Roč. 70, č. 5-6 (2024), s. 248-261
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/39889217 $y Pubmed
- 910 __
- $a ABA008 $b A 970 $c 89 $y p $z 0
- 990 __
- $a 20250213 $b ABA008
- 991 __
- $a 20250521143028 $b ABA008
- 999 __
- $a ok $b bmc $g 2324836 $s 1242483
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2024 $b 70 $c 5-6 $d 248-261 $e - $i 0015-5500 $m Folia biologica $n Folia Biol (Praha) $x MED00011004
- LZP __
- $b NLK116 $a Pubmed-20250213